Non-clear cell renal cell carcinoma narrative review: where we are in 2024.

ABSTRACT:

Background and objective

Advances in non-clear cell renal cell carcinoma (RCC) have lagged behind clear cell RCC due to the heterogeneity and relative rarity of the disease. However, more advanced molecular and genetic testing has allowed us to gain a more detailed and nuanced appreciation of these malignancies. This has laid the foundation for the identification of the distinct mutational and molecular patterns such as succinate dehydrogenase (SDH)-deficient RCC, fumarate hydratase (FH)-deficient RCC, and translocation RCC, so that clinicians can create a more personalized approach to their clinical management. Particularly for the rare non-papillary RCC variant histologies, clinical trial representation is lacking. In the discussed studies, no histology enrolled more than 29 pati

SUBMITTER: Pierro MJ 

PROVIDER: S-EPMC11651800 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature